Long acting GLP-1 receptor agonist (injectable)
Liraglutide flexible dose injection once daily
LIRA_SC_FLEX_1p2-1p8_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.69 (-1.21 to -0.17) | 0.34 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.26 (-4.12 to -0.38) | 0.77 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.26 (0.01 to 5.13) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.30 (0.10 to 0.87) | 0.88 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -4.85 (-7.65 to -2.06) | 0.83 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.68 (0.29 to 1.50) | 0.66 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.28 (0.89 to 6.43) | 0.38 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.29 (2.36 to 12.22) | 0.24 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.97 (1.10 to 8.90) | 0.46 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.90 (1.71 to 10.02) | 0.16 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.84 (0.22 to 3.62) | 0.68 |